Quantcast
Last updated on April 18, 2014 at 1:21 EDT

Five-Year Follow-Up Data on CERAMENT™|BONE VOID FILLER Demonstrates Long-Term Safety and Long-Lasting Bone Mineral Density Improvement in Osteoporotic Patients

October 28, 2013

Study was presented at the Combined Orthopaedic Research Society Meeting in Venice, Italy.

Lund, Sweden (PRWEB) October 28, 2013

BONESUPPORT AB, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, announced results from a five-year follow-up study on patients treated with CERAMENT™|BONE VOID FILLER, as presented at the Combined Orthopaedic Research Society (CORS) meeting in Venice, Italy. The study demonstrates long-term safety and long-lasting bone mineral density improvement, following bone remodeling after treatment with CERAMENT™|BONE VOID FILLER in osteoporotic patients.

“The study results confirm what we know to be true about CERAMENT™, its osteoconductive characteristics create a stable framework to support new bone growth, making it a safe and effective solution to filling voids such as correction osteotomies following malunited distal radius fractures,” said Professor Magnus Tägil, lead investigator in the study. “More importantly, the full bone remodeling seen within a year after CERAMENT™ treatment seems to be a long-lasting solution because the normalized bone mineral density persists at least for five years, as demonstrated in the present study.”

The aim of the study was to evaluate the long-term performance of CERAMENT™|BONE VOID FILLER in correction osteotomy following malunited distal radius fractures, a common complication after this fracture. Most often, an iliac crest bone graft is used to fill the void, however, this method is associated with a high incidence rate of donor site morbidity.

“We believe CERAMENT™|BONE VOID FILLER offers significant advantages over current treatment methods and we are pleased to see the positive outcomes demonstrated in this study,” said Lloyd Diamond, CEO of BONESUPPORT. “Studies such as this help improve and advance medical care and help health care decision makers direct resources to the strategies and treatments that work best.”

About BONESUPPORT

BONESUPPORT is an emerging leader of injectable bone graft substitutes for orthopedic trauma focusing on bone infection, instrument augmentation and spinal applications. CERAMENT™ is an injectable, synthetic bone substitute that mimics the properties of cancellous bone, allows for controlled resorption to support future bone ingrowth and is injectable under local anesthesia for minimally invasive surgery. CERAMENT’s unique biologic properties deliver a consistent, pre-packed and ready-to-use formulation to facilitate optimal delivery. CERAMENT™|G is the first CE-marked injectable antibiotic eluting ceramic bone graft substitute. CERAMENT™|G is indicated to promote and protect bone healing in the management of osteomyelitis, (bone infections) in CE marked countries. CERAMENT™|G is not available in the United States.

CERAMENT™ is a fully developed product platform that is commercially available in the U.S. and Europe and is revolutionizing the treatment of fragility and other fractures caused by disease and trauma. Scientific research of CERAMENT spans more than eleven years. Over forty-five pre-clinical, clinical and animal studies have been conducted and more than 6,000 patients have been treated with CERAMENT. The company was founded in 1999 and is based in Lund, Sweden with subsidiary locations in the US and Germany. To learn more about BONESUPPORT, please visit http://www.bonesupport.com.

For the original version on PRWeb visit: http://www.prweb.com/releases/2013/10/prweb11272027.htm


Source: prweb